[go: up one dir, main page]

AR060565A1 - Vacuna para la gripe aviaria y metodos de uso - Google Patents

Vacuna para la gripe aviaria y metodos de uso

Info

Publication number
AR060565A1
AR060565A1 ARP070101721A ARP070101721A AR060565A1 AR 060565 A1 AR060565 A1 AR 060565A1 AR P070101721 A ARP070101721 A AR P070101721A AR P070101721 A ARP070101721 A AR P070101721A AR 060565 A1 AR060565 A1 AR 060565A1
Authority
AR
Argentina
Prior art keywords
methods
vaccine
aviary
flu
vaccines
Prior art date
Application number
ARP070101721A
Other languages
English (en)
Original Assignee
Dow Agrosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc
Publication of AR060565A1 publication Critical patent/AR060565A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vacunas para la gripe, y en particular, con vacunas para la gripe aviaria (AIV). La presente comprende métodos para la preparacion de células de plantas transgénicas de manera de expresar polipéptidos de HA1 conocidos que tienen homologías especificadas, que se utilizan para la preparacion de composiciones de vacuna; y métodos para la induccion de la inmunidad protectora en un individuo, animal, mamífero o ser humano.
ARP070101721A 2006-04-21 2007-04-20 Vacuna para la gripe aviaria y metodos de uso AR060565A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79380406P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
AR060565A1 true AR060565A1 (es) 2008-06-25

Family

ID=39402309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101721A AR060565A1 (es) 2006-04-21 2007-04-20 Vacuna para la gripe aviaria y metodos de uso

Country Status (9)

Country Link
US (1) US7993655B2 (es)
EP (1) EP2010210A4 (es)
JP (1) JP2009535306A (es)
KR (1) KR20080109094A (es)
CN (1) CN101578111A (es)
AR (1) AR060565A1 (es)
BR (1) BRPI0710689A2 (es)
CA (1) CA2650091A1 (es)
WO (1) WO2008060669A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007261196A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
AU2008266702A1 (en) 2007-05-30 2008-12-24 Elenore S. Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN101978066A (zh) 2007-11-27 2011-02-16 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
CN102089432A (zh) 2008-07-08 2011-06-08 麦迪卡格公司 可溶性重组流感抗原
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2421546A1 (en) * 2009-04-23 2012-02-29 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
BRPI1015053A2 (pt) 2009-06-24 2019-07-09 Medicago Inc partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
WO2011079282A1 (en) * 2009-12-23 2011-06-30 Vaxgene Corporation Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules
TR201803560T4 (tr) 2009-09-22 2019-01-21 Medicago Inc Bitkiden türetilen proteinlerin hazırlanma metotları.
SG184804A1 (en) 2010-04-30 2012-11-29 Temasek Life Sciences Lab Ltd Universal vaccine against h5n1 lineages
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
WO2013013075A2 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
WO2013138334A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
US9493844B2 (en) 2012-12-13 2016-11-15 Dow Agrosciences Llc DNA detection methods for site specific nuclease activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885248A (en) 1984-02-15 1989-12-05 Lubrizol Genetics, Inc. Transfer vector
US5173410A (en) 1984-02-15 1992-12-22 Lubrizol Genetics Inc. Transfer vector
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
ATE108828T1 (de) 1987-02-09 1994-08-15 Lubrizol Genetics Inc Hybrides rns-virus.
CA2071943C (en) 1989-12-22 2007-04-24 Joan Tellefsen Odell Site-specific recombination of dna in plant cells
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
JPH07200893A (ja) 1993-12-27 1995-08-04 Toshiba Corp 自動精算機
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
JP2000253876A (ja) * 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
AU2001277050A1 (en) 2000-07-20 2002-02-05 The University Of Tennessee Research Corporation Materials and methods for the enhancement of effective root nodulation in legumes
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
DE10061150A1 (de) 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10109354A1 (de) 2001-02-27 2002-09-05 Icon Genetics Ag Rekombinante virale Schaltersysteme
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
JP2004535192A (ja) 2001-06-08 2004-11-25 イコン ジェネティクス インコーポレイティッド 植物中におけるタンパク質の産生
DE10129010A1 (de) 2001-06-13 2002-12-19 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10143205A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Verfahren zur Proteinproduktion in Pflanzen
JP4518741B2 (ja) 2002-04-29 2010-08-04 アイコン・ジェネティクス・ゲーエムベーハー 環境に安全なトランスジェニック生物を産生する方法
AU2004235800B2 (en) * 2003-05-05 2010-02-18 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2005049839A2 (en) 2003-11-10 2005-06-02 Icon Genetics Ag Rna virus-derived plant expression system

Also Published As

Publication number Publication date
US7993655B2 (en) 2011-08-09
EP2010210A2 (en) 2009-01-07
KR20080109094A (ko) 2008-12-16
CN101578111A (zh) 2009-11-11
CA2650091A1 (en) 2008-05-22
JP2009535306A (ja) 2009-10-01
WO2008060669A2 (en) 2008-05-22
US20090136532A1 (en) 2009-05-28
WO2008060669A3 (en) 2009-05-07
EP2010210A4 (en) 2010-07-21
BRPI0710689A2 (pt) 2012-02-22

Similar Documents

Publication Publication Date Title
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
CR9551A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
MX2018009917A (es) Vacuna contra el virus del zika.
MX381718B (es) Agentes biologicos y su uso en plantas.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CO6880050A2 (es) Composiciones y metodos para controlar la fusariosis
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
IT1397734B1 (it) Uso di estratti naturali di tannini e non tannini atti a migliorare la fertilita' del suolo e determinare un effetto starter sulle colture, e fitocomplesso di tannini e di non tannini per tale uso.
EA201070219A1 (ru) Полимерные мультиэпитопные вакцины против гриппа
CL2008002727A1 (es) Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos
UY36395A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
GT201100145A (es) Vacuna recombinante para influenza aviar y sus usos
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
ECSP099066A (es) Vacuna combinada estreptococica
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
AR087811A1 (es) Vacuna contra el staphylococcus aureus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal